Misfolded amyloid beta peptide (Ab) is a pathological hallmark of Alzheimer's disease (AD), a neurodegenerative illness characterized by cognitive deficits and neuronal loss. Transgenic mouse models of Ab over-production indicate that Ab-induced cognitive deficits occur in the absence of overt neuronal death, suggesting that while extensive neuronal death may be associated with later stages of the human disease, subtle physiological changes may underlie initial cognitive deficits. Therefore, identifying signaling elements involved in those Ab-induced cognitive impairments that occur prior to loss of neurons may reveal new potential pharmacological targets. Here, we report that the enzymatic activity of calcineurin, a key protein phosphatase involved in phosphorylation-dependent kinase activity crucial for synaptic plasticity and memory function, is upregulated in the CNS of the Tg2576 animal model for Ab over-production. Furthermore, acute treatment of Tg2576 mice with the calcineurin inhibitor FK506 (10 mg/kg i.p.) improves memory function. These results indicate that calcineurin may mediate some of the cognitive effects of excess Ab such that inhibition of calcineurin shall be further explored as a potential treatment to reverse cognitive impairments in AD.
Introduction
Alzheimer's disease (AD) is a terminal neurodegenerative illness characterized by cognitive deficits and extensive neuronal loss in the CNS (Selkoe and Schenk, 2003) . Hallmark features of AD are the presence of intracellular neurofibrillary tangles formed by hyperphosphorylated tau and the presence of high levels of the 40-and 42-amino acid long amyloid beta (Ab) peptide, which is generated through b-and c-secretase cleavage of the larger amyloid precursor protein (APP). At elevated levels, Ab peptides are prone to aggregation and eventually become a major component of the characteristic insoluble amyloid plaques that litter the extracellular space of the AD brain. While there is a general consensus that the presence of excess Ab is perhaps the most fundamental neurotoxic event in AD (Van Gassen and Annaert, 2003) , several lines of evidence indicate that oligomeric, soluble forms of Ab, rather than amyloid plaques, initiate the cognitive deficits characteristic of the disease (Cleary et al., 2005a; Glabe, 2006; Lesne et al., 2006) . For example, transgenic mouse models for AD in which Ab is over produced and accumulates in the CNS, develop memory impairments long before plaques are detected and in the absence of significant neuronal loss (Dineley, Xia, Bui, Sweatt, and Zheng, 2002; Irizarry, McNamara, Fedorchak, Hsiao, and Hyman, 1997; Takeuchi et al., 2000; Westerman et al., 2002) . Therefore, some of the cognitive impairments in AD may not be associated with extensive neuronal death; rather, they may be the result of more
